GSK’s acquisition, which comes amid other big money moves in the pharma industry, aims to broaden its asthma drug range. GSK’s acquisition will give the company access to Aiolos’ AIO-001, a monoclonal antibody that is ready to start…

  Zevra has obtained access to Acer’s rare disease assets Olpruva and Edsivo. Zevra Therapeutics has concluded its takeover of complete outstanding shares of Acer Therapeutics to form a rare disease company in a $91m deal. Zevra has obtained access…